What does Aptevo Therapeutics do?
Aptevo Therapeutics Inc. is a Seattle-based clinical-stage biotechnology company listed on the Nasdaq Capital Market under APVO. It develops antibody-like cancer medicines rather than selling approved products. The company’s central idea is controlled immune activation: engineer a molecule that binds a tumor-associated target and an immune-system target at the same time, concentrating the immune response where cancer cells are present. Aptevo describes this work through its proprietary ADAPTIR and ADAPTIR-FLEX platforms on its official company website.
Why is Aptevo best understood as one research segment?
The company reports one operating segment: discovery and development of novel oncology therapeutics. That matters because conventional segment-revenue analysis is not useful here. There is no commercial division financing the pipeline, no geographic sales mix, and no recurring product margin. Management allocates resources by comparing cash forecasts, net loss, operating cash use, and cash on hand. The analytical unit is therefore the portfolio of scientific programs and the probability that one or more programs reaches a value-creating clinical, regulatory, licensing, or commercialization milestone.
Who are the economic customers?
Patients and physicians are the ultimate users, but Aptevo’s near-term economic counterparties are different: clinical-trial sites, contract research and manufacturing organizations, research partners, grant providers, and potential pharmaceutical licensees. Until a medicine is approved, the company creates value through data, intellectual property, platform know-how, partnerships, and financing access rather than through unit sales.
How does Aptevo create economic value without product revenue?
Aptevo’s business model is an option-building model. Cash is invested in drug discovery, manufacturing, toxicology, regulatory preparation, and clinical trials. Each favorable result can increase the probability-adjusted value of a program, improve partnering terms, or justify the next trial. A failed safety signal, weak efficacy result, enrollment delay, or financing constraint can destroy part of that option value quickly.
What is proprietary about the platform?
The technology platform can create mono-, bi-, and multispecific proteins with different binding strengths and target combinations. ADAPTIR-FLEX can bind as many as four targets, giving scientists more design freedom than a conventional two-arm antibody. Aptevo’s practical claim is not merely “more targets”; it is controlled activation. The molecule should remain less active away from the tumor and become active when the required targets are brought together.
Where could future revenue come from?
Potential revenue sources include licensing upfront payments, development milestones, research funding, royalties, profit shares, and eventually product sales. The Alligator Bioscience collaboration for ALG.APV-527 contemplates shared development economics and equal sharing of third-party commercialization revenue when costs are shared equally. The May 2026 Niowave collaboration is structured 50/50 for up to three radiopharmaceutical programs. These structures can reduce Aptevo’s direct funding burden, but they also divide future economics and create dependence on partner execution.
Which pipeline assets matter most?
The pipeline has one clear lead asset, one partnered clinical solid-tumor program, and a broader preclinical portfolio. The official mipletamig program page describes a CD3×CD123 bispecific designed to redirect T cells toward leukemia cells. That clinical program carries most of the near-term value because it has human efficacy and safety data, a defined trial path, and an expected Phase 2 dose-selection milestone.
How concentrated is research spending?
FY2025 research and development expense was $14.54 million. Mipletamig absorbed $6.58 million, ALG.APV-527 absorbed $0.48 million, and preclinical research and discovery absorbed $7.48 million. The mix shows that Aptevo is not a one-asset laboratory, but it also highlights a strategic tension: advancing a broad platform can preserve upside while consuming scarce capital that might otherwise accelerate the lead clinical program.
What does the most recent clinical update indicate?
The May 6, 2026 RAINIER update covered 31 evaluable frontline AML patients through Cohort 5, including four patients from the prior dose-expansion study. Aptevo reported an 87% clinical-benefit rate, an 81% CR/CRi remission rate, a 65% complete-remission rate, and no cytokine-release syndrome in frontline patients. Among patients achieving CR/CRi, 52% reached measurable-residual-disease negativity. These are encouraging early-stage results, but they are interim, non-randomized, and derived from a small dataset; later cohorts and Phase 2 evidence must confirm them.
What strategic turning points shape Aptevo today?
Aptevo’s current identity reflects repeated narrowing and rebuilding: a corporate spinout, disposal of commercial assets, concentration on immuno-oncology, platform partnerships, and frequent financing. The relevant history is not corporate trivia; it explains why the company owns scientific platforms but lacks commercial revenue, why partnerships matter, and why dilution is central to shareholder analysis.
-
2016
Aptevo separated from Emergent BioSolutions as an independent biotechnology company. The spinout created a standalone public entity centered on oncology and hematology assets.
-
2017
Aptevo and Alligator Bioscience began the collaboration that produced ALG.APV-527, establishing a model in which platform science, development cost, and future economics are shared.
-
2019
The FDA granted orphan-drug designation to mipletamig for AML, adding potential regulatory and market-exclusivity benefits if the program eventually receives approval.
-
2025
The company increased mipletamig spending to $6.58 million for FY2025 while completing ALG.APV-527 dose escalation and raising substantial equity capital to rebuild liquidity.
-
April 2026
Jeff Lamothe became President and CEO while former CEO Marvin White moved to Executive Chair, preserving strategic continuity while shifting day-to-day execution leadership.
-
May–June 2026
The 50/50 Niowave collaboration expanded Aptevo into radiopharmaceuticals, and a $1.5 million non-dilutive CARE Fund grant supported IND-enabling work for APVO451.
What changed in 2026?
Three developments broadened the story beyond the RAINIER trial. First, the executive transition placed a finance-and-strategy veteran in the CEO role. Second, the Niowave collaboration paired Aptevo’s Nectin-4 targeting assets with isotope production, including Actinium-225. Third, the $1.5 million APVO451 grant provided external, non-dilutive support for development-candidate selection targeted by year-end 2026 and planned IND-enabling work beginning in the first quarter of 2027.
What does the latest reported period show?
The latest complete financial filing is the Form 10-Q for the quarter ended March 31, 2026. It confirms that Aptevo remains a pre-revenue research company whose operating performance is best measured by clinical progress, expense discipline, cash consumption, and financing capacity.
How did Q1 2026 compare with Q1 2025?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Mipletamig R&D | $1.93M | $1.62M | Higher spending reflects the lead program’s advancing trial work. |
| ALG.APV-527 R&D | $0.03M | $0.18M | Expense fell after dose escalation concluded. |
| Preclinical and discovery R&D | $1.97M | $1.83M | Broad platform development remained roughly half of R&D. |
| Total R&D | $3.92M | $3.63M | Expense increased 8.0%, primarily from mipletamig and employee costs. |
| G&A | $2.80M | $2.80M | Corporate overhead was stable year over year. |
| Net loss | $6.70M | $6.41M | Loss widened modestly as research spending increased. |
| Operating cash used | $7.97M | $6.58M | Cash burn increased 21.1%, partly because working-capital movements exceeded accounting loss. |
How was Q1 research spending distributed?
How financially strong is Aptevo?
The balance sheet is liquid relative to current liabilities but weak relative to the recurring cost of development. Cash was $14.53 million at March 31, 2026, down from $21.62 million at December 31, 2025. Current assets were $15.98 million versus current liabilities of $4.76 million, producing a current ratio of about 3.4 times. That ratio looks comfortable in isolation, but Q1 operating cash use of $7.97 million consumed more than half of quarter-end cash on an annualized basis.
What does the FY2025 baseline reveal?
| FY2025 measure | Amount | Why it matters |
|---|---|---|
| R&D expense | $14.54M | Core investment in clinical and preclinical programs. |
| G&A expense | $11.77M | A high overhead burden relative to a company with no product revenue. |
| Operating loss | $26.31M | Represents the recurring funding gap before other income. |
| Net loss | $25.97M | The company remained structurally unprofitable. |
| Operating cash used | $25.59M | Cash burn closely tracked accounting loss. |
| Financing cash provided | $38.50M | Equity financing, rather than operations, increased cash. |
| Accumulated deficit | $275.12M | Shows the long cumulative cost of development. |
Why does the going-concern language matter?
Both management and the board concluded that substantial doubt exists about Aptevo’s ability to continue as a going concern for one year after issuance of the Q1 2026 statements. This does not mean failure is certain. It means existing committed resources and expected operations do not independently remove financing uncertainty. The $60 million standby equity facility may extend flexibility, but its usefulness depends on market conditions, share-price capacity, issuance limits, and the cost of dilution.
Who competes with Aptevo, and what is its advantage?
Aptevo competes in a field where scientific differentiation is necessary but not sufficient. Larger pharmaceutical companies can run more trials, recruit faster, manufacture at scale, and absorb failures. Smaller platform biotechs may move faster or design more specialized molecules. The FY2025 Form 10-K names CD123 competitors including Affimed, Innate Pharma/Sanofi, MacroGenics/Gilead, Xencor-related programs, Menarini, Molecular Partners, LAVA, and Sanofi, alongside non-CD123 AML approaches and CAR-T programs.
| Competitive arena | Representative pressure | Aptevo’s intended differentiation | Unresolved question |
|---|---|---|---|
| Frontline AML | Venetoclax-based standard of care plus emerging CD123 and non-CD123 therapies | Add mipletamig without materially worsening cytokine-release toxicity | Will larger, later-stage trials confirm remission and safety? |
| 4-1BB solid tumors | FAP×4-1BB, PD-L1×4-1BB, HER2×4-1BB, ADC, and T-cell-engager programs | Require 5T4-dependent crosslinking to focus activation in tumors | Can stable disease translate into objective responses and durable benefit? |
| Trispecific solid tumors | Rapid innovation by antibody, cell-therapy, ADC, and radiopharmaceutical developers | Coordinate tumor targeting, antigen-presenting-cell activation, and T-cell engagement | Can the added complexity remain manufacturable and tolerable? |
| Radiopharmaceuticals | Well-capitalized pharma entrants and isotope-supply constraints | Combine multispecific targeting with Niowave’s isotope supply and manufacturing | Can the partnership generate differentiated preclinical proof quickly? |
What could form a real moat?
The strongest possible moat is a portfolio-level learning loop: clinical evidence from mipletamig validates the CRIS-7-derived CD3 approach; that knowledge informs APVO451 and other CD3-containing molecules; platform flexibility enables new target combinations; and partnerships provide modalities Aptevo does not own internally. Patent protection, proprietary constructs, biological know-how, and clinical data can reinforce one another. However, the moat remains provisional until controlled trials show outcomes that competitors cannot easily match.
Who owns Aptevo stock, and how is it governed?
Aptevo has one class of common voting stock and does not have a founder-controlled dual-class structure. That makes capital providers, warrant holders, strategic investors, and the board more important than founder voting power. Ownership changes rapidly because the company repeatedly issues shares and warrants, so every percentage must be read with its source date.
| Holder or governance group | Officially reported position | Source period | Why it matters |
|---|---|---|---|
| Niowave, Inc. | 151,723 shares; 12.2% reported beneficial ownership | Event date May 25, 2026 | A strategic partner also became a material shareholder, aligning development and equity incentives. |
| Executive officers and directors as a group | Less than 1% in the 2025 proxy table | June 20, 2025 record date | Economic control was dispersed rather than insider-dominated. |
| Board of directors | Six members; three classified groups in the 2025 proxy | 2025 annual-meeting materials | A classified board slows full board turnover and can support strategic continuity. |
| Common shareholders | 1.20M shares outstanding at March 31, 2026; 1.25M at May 13, 2026 | Q1 2026 filing | The rising count illustrates ongoing issuance and per-share dilution risk. |
Why is Niowave’s stake more important than a passive holding?
The Niowave Schedule 13G reported 151,723 shares and 12.18% beneficial ownership. The collaboration announcement also described warrants and potential future purchases that could lift ownership toward 19.99%, subject to the agreement. Niowave is therefore both a scientific counterparty and a capital-allocation signal: it contributes isotope capabilities while bearing direct exposure to Aptevo’s equity outcome.
What does governance signal?
The 2025 proxy statement showed a six-member classified board and one voting class. In 2026, leadership shifted without a wholesale strategy reset: Jeff Lamothe became CEO and Marvin White became Executive Chair. That structure can preserve institutional memory, but the board’s most consequential duty remains balancing scientific ambition against liquidity, dilution, listing compliance, and partnership terms.
Which growth opportunities could change the story?
Aptevo’s upside is not a smooth forecast; it is a sequence of milestone-driven branches. The highest-value branch is mipletamig advancing into Phase 2 with a dose and safety profile that supports a credible development plan. The second branch is turning platform breadth into external validation through grants, collaborations, or licenses. The third is demonstrating that controlled immune activation can extend from blood cancer into solid tumors and radiopharmaceuticals.
How can partnerships improve capital efficiency?
| Capital source or mechanism | Reported scale | Benefit | Trade-off |
|---|---|---|---|
| Standby equity facility | $60.0M announced in January 2026 | Flexible access to capital over time | Issuance depends on market conditions and can dilute existing holders |
| Niowave strategic investment | 12.2% reported beneficial stake in June 2026 filing | Capital alignment plus isotope supply and development capability | Potential ownership expansion changes the shareholder base |
| CARE Fund grant | $1.5M announced June 30, 2026 | Non-dilutive funding and third-party scientific validation | Restricted to the supported APVO451 research scope |
| Alligator collaboration | 50% shared costs disclosed for ALG.APV-527 | Reduces sole funding burden and combines capabilities | Future revenue and decision rights are shared |
What risks and KPIs should researchers monitor?
Aptevo’s risk profile is unusually concentrated. Clinical data, liquidity, and dilution can each change the valuation faster than conventional revenue or margin trends. The company also faces Nasdaq listing risk, dependence on third parties, intellectual-property challenges, manufacturing complexity, and competition from better-funded developers.
| Risk | Current factual anchor | Financial or strategic effect | What to monitor |
|---|---|---|---|
| Clinical translation | 31 evaluable frontline AML patients in May 2026 update | Later data may differ from encouraging interim remission results | Cohorts 6–7, durability, safety, MRD negativity, and Phase 2 design |
| Liquidity | $14.53M cash at March 31, 2026; $7.97M Q1 operating cash use | Insufficient runway could slow trials or weaken negotiating leverage | Quarter-end cash, committed financing, grant receipts, and burn |
| Dilution | 1.20M shares at March 31 and 1.25M at May 13, 2026 | Enterprise value may rise while value per existing share falls | Shares, warrants, SEPA draws, exercise prices, and ownership limits |
| Partner execution | Alligator and Niowave programs depend on shared work | Delays, opt-outs, or changed priorities can reduce pipeline value | Stage gates, program selection, isotope supply, and cost-sharing |
| Listing compliance | The 10-K identifies future Nasdaq delisting risk | Lower liquidity and financing access could intensify | Bid price, stockholders’ equity, reverse splits, and Nasdaq notices |
Which operating KPIs matter most?
What is the key takeaway for valuation?
A conventional revenue-multiple analysis is not sufficient because Aptevo has no product revenue and negative free cash flow. A practical valuation starts with program-level probability-adjusted cash flows, subtracts corporate burn and future development costs, adds cash and credible non-dilutive resources, and then divides by a fully diluted share count that reflects warrants and likely future issuance. The discount rate must reflect clinical, financing, regulatory, and small-company execution risk.
| Valuation driver | Current evidence | Upside mechanism | Downside mechanism |
|---|---|---|---|
| Mipletamig probability of success | Encouraging 31-patient interim frontline AML dataset | Stable efficacy, safety, and a credible Phase 2 design raise probability-adjusted value | Regression in response, safety, or durability lowers value sharply |
| Time and cost to approval | Phase 1b dose optimization remains underway in 2026 | Efficient development or partnership reduces future funding needs | Larger trials, delays, and manufacturing work increase required capital |
| Platform optionality | Two clinical candidates, six preclinical candidates, and up to three Niowave programs | New grants, licenses, or proof-of-concept programs create additional options | Portfolio breadth consumes cash without guaranteeing validation |
| Cash and dilution | $14.53M cash at March 31, 2026 and substantial equity facilities | Strategic or non-dilutive capital extends runway to catalysts | Low-price issuance transfers value away from existing shares |
| Partner economics | 50/50 structures with Alligator and Niowave | Shared costs and capabilities improve capital efficiency | Aptevo retains only part of successful program economics |
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.